Network-Attached Storage Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032
Description
Network-Attached Storage Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032
Growth Factors of Network Attached Storage Market
The global nylon market size was valued at USD 34.62 billion in 2023 and is projected to grow from USD 40.33 billion in 2024 to USD 129.52 billion by 2032, exhibiting a CAGR of 15.77% during the forecast period of 2024-2032.
The COVID-19 pandemic has reshaped the Network Attached Storage (NAS) market appreciably. The surge in far off paintings has fueled call for for NAS answers to facilitate stable information get entry to and collaboration. Additionally, the exponential increase in information volumes has underscored the want for scalable storage answers with strong security and backup capabilities. Organizations are an increasing number of adopting hybrid and cloud-local NAS solutions to fulfill evolving commercial enterprise wishes.
The Network Attached Storage (NAS) market is propelled with the aid of the developing need for scalable storage solutions because of exponential facts increase, elevated demand for remote work collaboration equipment, prioritization of information protection, adoption of hybrid and cloud-local NAS answers, and improvements in edge computing and AI-driven analytics.
The community-connected storage (NAS) marketplace is exploding, with increase fees exceeding 15% anticipated by analysts. This surge is driven by way of a tidal wave of records –from smartphones and the Internet of Things (IoT) – that businesses and purchasers conflict to comprise.The trend is not pretty much bigger containers; NAS gadgets are morphing into mini-records centers, offering functions like cloud integration, AI-powered facts management, or even help for virtual machines. It's an atypical new global in which your NAS may be your non-public information powerhouse.
Comprehensive Analysis of Network Attached Storage Market
The segmentation of the network attached garage (NAS) marketplace consists of company type and garage answer analysis. In phrases of organization kind, the marketplace is categorized into Small Office/Home Office (SoHo), mid-size, and big firms. Mid-size establishments lead the market because of the provision of customized NAS answers presenting scalability and price effectiveness. SoHo and large establishments are anticipated to peer consistent growth, driven by way of the demand for NAS solutions in clever metropolis tasks and worldwide data centers. Regarding garage solutions, the market comprises scale-up NAS and scale-out NAS. Scale-up NAS devices dominate the market because of their economic viability and efficiency, even as scale-out NAS gadgets are projected to grow rapidly in recognition because of their functionality to guide excessive-capacity, excessive overall performance workloads with low latency.
The North American region led the medical devices market by benefitting a size of USD 14.68 billion in 2023 due to multiplied virtual infrastructure, linked devices, increasing adoption of artificial intelligence (AI)-based solutions, and the volumes of facts from organizations. In addition, NAS plays a crucial component in the information middle garage area.
The key players in the network attached storage (NAS) market significantly shape its growth trajectory and establish industry benchmarks. These influential companies, including Dell Technologies Inc. (U.S.), IBM Corporation (U.S.), QNAP Systems, Inc. (Taiwan), Hitachi Vantara LLC (Hitachi Ltd.) (Japan), Western Digital Corporation (U.S.), Seagate Technology Holdings plc (Ireland), Synology Inc. (Taiwan), Buffalo Americas, Inc. (U.S.), NetApp, Inc. (U.S.), and NetGear, Inc. (U.S.), contribute to a competitive landscape, driving innovation and market advancement.
Ugreen partnered with Intel to introduce the UGREEN NASync line of network connected garage gadgets, proposing computerized choice-making competencies and superior garage performance.
Segmentation Table
ATTRIBUTE DETAILS
Study Period 2019-2032
Base Year 2023
Estimated Year 2024
Forecast Period 2024-2032
Historical Period 2019-2022
Growth Rate CAGR of 15.7% from 2024 to 2032
Unit Value (USD Billion)
Segmentation By Enterprise Type
SoHo: <10 FTEs
Mid-size: <1,000 FTEs
Large Enterprise: >1,000 FTEs
By Storage Solution
Scale-up NAS
Scale-out NAS
By Region
North America (By Enterprise Type, By Storage Solution, and By Country)
- US
- Canada
- Mexico
South America (By Enterprise Type, By Storage Solution, and By Country)
- Brazil
- Argentina
- Rest of South America
Europe (By Enterprise Type, By Storage Solution, and By Country)
- UK
- Germany
- France
- Italy
- Spain
- Russia
- Benelux
- Nordics
- Rest of Europe
Middle East & Africa (By Enterprise Type, By Storage Solution, and By Country)
- Turkey
- Israel
- GCC Countries
- North Africa
- South Africa
- Rest of MEA
Asia Pacific (By Enterprise Type, By Storage Solution, and By Country)
- China
- India
- Japan
- South Korea
- ASEAN
- Oceania
- Rest of APAC
Please Note: It will take 5-6 business days to complete the report upon order confirmation.
Table of Contents
107 Pages
- 1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.4. Definitions and Assumptions
- 2. Executive Summary
- 3. Market Dynamics
- 3.1. Market Drivers
- 3.2. Market Restraints
- 3.3. Market Opportunities
- 3.4. Market Trends
- 4. Key Insights
- 4.1. Prevalence of Major Ophthalmic Diseases, in Key Countries/ Region, 2023
- 4.2. Pipeline Analysis, By Key Players
- 4.3. Patent Snapshot, By Key Players
- 4.4. Key Industry Developments – Merges, Acquisitions and Partnerships
- 4.5. Regulatory Scenario for Key Countries
- 4.6. Reimbursement Scenario for Key Countries
- 4.7. Impact of COVID-19 on the Market
- 5. Global Ophthalmic Disease Therapeutics Market Analysis, Insights and Forecast, 2019-2032
- 5.1. Market Analysis, Insights and Forecast – By Drug Class
- 5.1.1. Anti-inflammatory
- 5.1.2. Anti-infectives
- 5.1.3. Anti-VEGF
- 5.1.4. Anti-glaucoma
- 5.1.4.1. Beta Blockers
- 5.1.4.2. Prostaglandins Analogs
- 5.1.4.3. Alpha Adrenergic Agonists
- 5.1.4.4. Carbonic Anhydrase Inhibitors
- 5.1.4.5. Combination Drugs
- 5.1.4.6. Others
- 5.1.5. Others
- 5.2. Market Analysis, Insights and Forecast – By Dosage Form
- 5.2.1. Solid
- 5.2.2. Liquid
- 5.2.3. Semisolid
- 5.3. Market Analysis, Insights and Forecast – By Disease Indication
- 5.3.1. Glaucoma
- 5.3.1.1. Open Angle Glaucoma
- 5.3.1.2. Angle Closure Glaucoma
- 5.3.1.3. Others
- 5.3.2. Dry Eye Disease
- 5.3.3. Retinal Diseases
- 5.3.3.1. Diabetic Macular Edema (DME)
- 5.3.3.2. Macular Degeneration (AMD)
- 5.3.3.3. Diabetic Retinopathy (DR)
- 5.3.3.4. Retinal Vein Occlusion (RVO)
- 5.3.3.5. Others
- 5.3.4. Allergy & Infections
- 5.3.5. Others
- 5.4. Market Analysis, Insights and Forecast – By Distribution Channel
- 5.4.1. Hospital Pharmacies
- 5.4.2. Retail & Online Pharmacies
- 5.5. Market Analysis, Insights and Forecast – By Region
- 5.5.1. North America
- 5.5.2. Europe
- 5.5.3. Asia Pacific
- 5.5.4. Latin America
- 5.5.5. Middle East & Africa
- 6. North America Ophthalmic Disease Therapeutics Market Analysis, Insights and Forecast, 2019-2032
- 6.1. Market Analysis, Insights and Forecast – By Drug Class
- 6.1.1. Anti-inflammatory
- 6.1.2. Anti-infectives
- 6.1.3. Anti-VEGF
- 6.1.4. Anti-glaucoma
- 6.1.4.1. Beta Blockers
- 6.1.4.2. Prostaglandins Analogs
- 6.1.4.3. Alpha Adrenergic Agonists
- 6.1.4.4. Carbonic Anhydrase Inhibitors
- 6.1.4.5. Combination Drugs
- 6.1.4.6. Others
- 6.1.5. Others
- 6.2. Market Analysis, Insights and Forecast – By Dosage Form
- 6.2.1. Solid
- 6.2.2. Liquid
- 6.2.3. Semisolid
- 6.3. Market Analysis, Insights and Forecast – By Disease Indication
- 6.3.1. Glaucoma
- 6.3.1.1. Open Angle Glaucoma
- 6.3.1.2. Angle Closure Glaucoma
- 6.3.1.3. Others
- 6.3.2. Dry Eye Disease
- 6.3.3. Retinal Diseases
- 6.3.3.1. Diabetic Macular Edema (DME)
- 6.3.3.2. Macular Degeneration (AMD)
- 6.3.3.3. Diabetic Retinopathy (DR)
- 6.3.3.4. Retinal Vein Occlusion (RVO)
- 6.3.3.5. Others
- 6.3.4. Allergy & Infections
- 6.3.5. Others
- 6.4. Market Analysis, Insights and Forecast – By Distribution Channel
- 6.4.1. Hospital Pharmacies
- 6.4.2. Retail & Online Pharmacies
- 6.5. Market Analysis, Insights and Forecast – By Country
- 6.5.1. U.S.
- 6.5.2. Canada
- 7. Europe Ophthalmic Disease Therapeutics Market Analysis, Insights and Forecast, 2019-2032
- 7.1. Market Analysis, Insights and Forecast – By Drug Class
- 7.1.1. Anti-inflammatory
- 7.1.2. Anti-infectives
- 7.1.3. Anti-VEGF
- 7.1.4. Anti-glaucoma
- 7.1.4.1. Beta Blockers
- 7.1.4.2. Prostaglandins Analogs
- 7.1.4.3. Alpha Adrenergic Agonists
- 7.1.4.4. Carbonic Anhydrase Inhibitors
- 7.1.4.5. Combination Drugs
- 7.1.4.6. Others
- 7.1.5. Others
- 7.2. Market Analysis, Insights and Forecast – By Dosage Form
- 7.2.1. Solid
- 7.2.2. Liquid
- 7.2.3. Semisolid
- 7.3. Market Analysis, Insights and Forecast – By Disease Indication
- 7.3.1. Glaucoma
- 7.3.1.1. Open Angle Glaucoma
- 7.3.1.2. Angle Closure Glaucoma
- 7.3.1.3. Others
- 7.3.2. Dry Eye Disease
- 7.3.3. Retinal Diseases
- 7.3.3.1. Diabetic Macular Edema (DME)
- 7.3.3.2. Macular Degeneration (AMD)
- 7.3.3.3. Diabetic Retinopathy (DR)
- 7.3.3.4. Retinal Vein Occlusion (RVO)
- 7.3.3.5. Others
- 7.3.4. Allergy & Infections
- 7.3.5. Others
- 7.4. Market Analysis, Insights and Forecast – By Distribution Channel
- 7.4.1. Hospital Pharmacies
- 7.4.2. Retail & Online Pharmacies
- 7.5. Market Analysis, Insights and Forecast – By Country/ Sub-region
- 7.5.1. U.K
- 7.5.2. Germany
- 7.5.3. France
- 7.5.4. Spain
- 7.5.5. Italy
- 7.5.6. Scandinavia
- 7.5.7. Rest of Europe
- 8. Asia Pacific Ophthalmic Disease Therapeutics Market Analysis, Insights and Forecast, 2019-2032
- 8.1. Market Analysis, Insights and Forecast – By Drug Class
- 8.1.1. Anti-inflammatory
- 8.1.2. Anti-infectives
- 8.1.3. Anti-VEGF
- 8.1.4. Anti-glaucoma
- 8.1.4.1. Beta Blockers
- 8.1.4.2. Prostaglandins Analogs
- 8.1.4.3. Alpha Adrenergic Agonists
- 8.1.4.4. Carbonic Anhydrase Inhibitors
- 8.1.4.5. Combination Drugs
- 8.1.4.6. Others
- 8.1.5. Others
- 8.2. Market Analysis, Insights and Forecast – By Dosage Form
- 8.2.1. Solid
- 8.2.2. Liquid
- 8.2.3. Semisolid
- 8.3. Market Analysis, Insights and Forecast – By Disease Indication
- 8.3.1. Glaucoma
- 8.3.1.1. Open Angle Glaucoma
- 8.3.1.2. Angle Closure Glaucoma
- 8.3.1.3. Others
- 8.3.2. Dry Eye Disease
- 8.3.3. Retinal Diseases
- 8.3.3.1. Diabetic Macular Edema (DME)
- 8.3.3.2. Macular Degeneration (AMD)
- 8.3.3.3. Diabetic Retinopathy (DR)
- 8.3.3.4. Retinal Vein Occlusion (RVO)
- 8.3.3.5. Others
- 8.3.4. Allergy & Infections
- 8.3.5. Others
- 8.4. Market Analysis, Insights and Forecast – By Distribution Channel
- 8.4.1. Hospital Pharmacies
- 8.4.2. Retail & Online Pharmacies
- 8.5. Market Analysis, Insights and Forecast – By Country/ Sub-region
- 8.5.1. Japan
- 8.5.2. China
- 8.5.3. India
- 8.5.4. Australia
- 8.5.5. Southeast Asia
- 8.5.6. Rest of Asia Pacific
- 9. Latin America Ophthalmic Disease Therapeutics Market Analysis, Insights and Forecast, 2019-2032
- 9.1. Market Analysis, Insights and Forecast – By Drug Class
- 9.1.1. Anti-inflammatory
- 9.1.2. Anti-infectives
- 9.1.3. Anti-VEGF
- 9.1.4. Anti-glaucoma
- 9.1.4.1. Beta Blockers
- 9.1.4.2. Prostaglandins Analogs
- 9.1.4.3. Alpha Adrenergic Agonists
- 9.1.4.4. Carbonic Anhydrase Inhibitors
- 9.1.4.5. Combination Drugs
- 9.1.4.6. Others
- 9.1.5. Others
- 9.2. Market Analysis, Insights and Forecast – By Dosage Form
- 9.2.1. Solid
- 9.2.2. Liquid
- 9.2.3. Semisolid
- 9.3. Market Analysis, Insights and Forecast – By Disease Indication
- 9.3.1. Glaucoma
- 9.3.1.1. Open Angle Glaucoma
- 9.3.1.2. Angle Closure Glaucoma
- 9.3.1.3. Others
- 9.3.2. Dry Eye Disease
- 9.3.3. Retinal Diseases
- 9.3.3.1. Diabetic Macular Edema (DME)
- 9.3.3.2. Macular Degeneration (AMD)
- 9.3.3.3. Diabetic Retinopathy (DR)
- 9.3.3.4. Retinal Vein Occlusion (RVO)
- 9.3.3.5. Others
- 9.3.4. Allergy & Infections
- 9.3.5. Others
- 9.4. Market Analysis, Insights and Forecast – By Distribution Channel
- 9.4.1. Hospital Pharmacies
- 9.4.2. Retail & Online Pharmacies
- 9.5. Market Analysis, Insights and Forecast – By Country/ Sub-region
- 9.5.1. Brazil
- 9.5.2. Mexico
- 9.5.3. Rest of Latin America
- 10. Middle East & Africa Ophthalmic Disease Therapeutics Market Analysis, Insights and Forecast, 2019-2032
- 10.1. Market Analysis, Insights and Forecast – By Drug Class
- 10.1.1. Anti-inflammatory
- 10.1.2. Anti-infectives
- 10.1.3. Anti-VEGF
- 10.1.4. Anti-glaucoma
- 10.1.4.1. Beta Blockers
- 10.1.4.2. Prostaglandins Analogs
- 10.1.4.3. Alpha Adrenergic Agonists
- 10.1.4.4. Carbonic Anhydrase Inhibitors
- 10.1.4.5. Combination Drugs
- 10.1.4.6. Others
- 10.1.5. Others
- 10.2. Market Analysis, Insights and Forecast – By Dosage Form
- 10.2.1. Solid
- 10.2.2. Liquid
- 10.2.3. Semisolid
- 10.3. Market Analysis, Insights and Forecast – By Disease Indication
- 10.3.1. Glaucoma
- 10.3.1.1. Open Angle Glaucoma
- 10.3.1.2. Angle Closure Glaucoma
- 10.3.1.3. Others
- 10.3.2. Dry Eye Disease
- 10.3.3. Retinal Diseases
- 10.3.3.1. Diabetic Macular Edema (DME)
- 10.3.3.2. Macular Degeneration (AMD)
- 10.3.3.3. Diabetic Retinopathy (DR)
- 10.3.3.4. Retinal Vein Occlusion (RVO)
- 10.3.3.5. Others
- 10.3.4. Allergy & Infections
- 10.3.5. Others
- 10.4. Market Analysis, Insights and Forecast – By Distribution Channel
- 10.4.1. Hospital Pharmacies
- 10.4.2. Retail & Online Pharmacies
- 10.5. Market Analysis, Insights and Forecast – By Country/ Sub-region
- 10.5.1. GCC
- 10.5.2. South Africa
- 10.5.3. Rest of Middle East & Africa
- 11. Competitive Analysis
- 11.1. Global Market Share Analysis (2023)
- 11.2. Company Profiles
- 11.2.1. Viatris Inc.
- 11.2.1.1. Overview
- 11.2.1.2. Products & Services
- 11.2.1.3. SWOT Analysis
- 11.2.1.4. Recent Developments
- 11.2.1.5. Strategies
- 11.2.1.6. Financials (Based on Availability)
- 11.2.2. Novartis AG
- 11.2.2.1. Overview
- 11.2.2.2. Products & Services
- 11.2.2.3. SWOT Analysis
- 11.2.2.4. Recent Developments
- 11.2.2.5. Strategies
- 11.2.2.6. Financials (Based on Availability)
- 11.2.3. AbbVie Inc.
- 11.2.3.1. Overview
- 11.2.3.2. Products & Services
- 11.2.3.3. SWOT Analysis
- 11.2.3.4. Recent Developments
- 11.2.3.5. Strategies
- 11.2.3.6. Financials (Based on Availability)
- 11.2.4. F. Hoffmann-La Roche Ltd.
- 11.2.4.1. Overview
- 11.2.4.2. Products & Services
- 11.2.4.3. SWOT Analysis
- 11.2.4.4. Recent Developments
- 11.2.4.5. Strategies
- 11.2.4.6. Financials (Based on Availability)
- 11.2.5. Regeneron Pharmaceuticals, Inc.
- 11.2.5.1. Overview
- 11.2.5.2. Products & Services
- 11.2.5.3. SWOT Analysis
- 11.2.5.4. Recent Developments
- 11.2.5.5. Strategies
- 11.2.5.6. Financials (Based on Availability)
- 11.2.6. Santen Pharmaceutical Co., Ltd.
- 11.2.6.1. Overview
- 11.2.6.2. Products & Services
- 11.2.6.3. SWOT Analysis
- 11.2.6.4. Recent Developments
- 11.2.6.5. Strategies
- 11.2.6.6. Financials (Based on Availability)
- 11.2.7. Bayer AG
- 11.2.7.1. Overview
- 11.2.7.2. Products & Services
- 11.2.7.3. SWOT Analysis
- 11.2.7.4. Recent Developments
- 11.2.7.5. Strategies
- 11.2.7.6. Financials (Based on Availability)
- 11.2.8. Bausch & Lomb Incorporated
- 11.2.8.1. Overview
- 11.2.8.2. Products & Services
- 11.2.8.3. SWOT Analysis
- 11.2.8.4. Recent Developments
- 11.2.8.5. Strategies
- 11.2.8.6. Financials (Based on Availability)
- 11.2.9. Merck KGaA
- 11.2.9.1. Overview
- 11.2.9.2. Products & Services
- 11.2.9.3. SWOT Analysis
- 11.2.9.4. Recent Developments
- 11.2.9.5. Strategies
- 11.2.9.6. Financials (Based on Availability)
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
